Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation

Area of Science:

• Neuroscience
• Pharmacology
• Drug Delivery Systems

Background:

• Parkinson's disease (PD) management relies on levodopa (LD), but its short half-life and limited absorption pose challenges.
• Current oral LD formulations require frequent dosing and can lead to fluctuating plasma concentrations.
• IPX203 is a novel oral extended-release (ER) formulation of carbidopa (CD) and levodopa (LD) designed to overcome these limitations.

Purpose of the Study:

• To present the formulation strategy of IPX203.
• To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) profile of IPX203.
• To compare IPX203 with immediate-release (IR) CD-LD in advanced PD patients.

Main Methods:

• A Phase 2, open-label, rater-blinded, multicenter, crossover study compared IPX203 with IR CD-LD.
• PK and PD parameters were assessed in advanced PD patients.
• Studies in healthy volunteers examined the effect of food and administration on a vehicle.

Main Results:

• IPX203 sustained LD concentrations above 50% of peak for 6.2 hours versus 3.9 hours for IR CD-LD (P=.0002).
• Mean MDS-UPDRS Part III scores were significantly lower with IPX203 prior to the first daily dose (LS mean difference -8.1, P=.0255).
• Food intake delayed Tmax by 2 hours and increased Cmax and AUC by ~20%; sprinkling on applesauce had no effect.

Conclusions:

• IPX203's innovative design effectively addresses limitations of oral LD delivery.
• The ER formulation provides sustained therapeutic levodopa levels.
• IPX203 demonstrates potential for improved motor symptom control in Parkinson's disease.